Dicerna Pharmaceuticals Inc (DRNA) Receives $21.78 Average PT from Analysts

Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) have received a consensus rating of “Buy” from the twelve research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.88.

DRNA has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, March 12th. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th. Chardan Capital upgraded Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a report on Tuesday, January 22nd. SunTrust Banks increased their price target on Dicerna Pharmaceuticals to $26.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th. Finally, B. Riley increased their price target on Dicerna Pharmaceuticals from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th.

NASDAQ DRNA traded up $0.07 on Wednesday, reaching $13.40. The company had a trading volume of 6,473 shares, compared to its average volume of 858,823. The company has a market capitalization of $909.91 million, a PE ratio of -11.39 and a beta of 2.40. Dicerna Pharmaceuticals has a 52 week low of $8.71 and a 52 week high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $1.54 million during the quarter, compared to the consensus estimate of $8.38 million. Dicerna Pharmaceuticals had a negative net margin of 1,438.68% and a negative return on equity of 53.27%. On average, equities research analysts predict that Dicerna Pharmaceuticals will post -0.99 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Dicerna Pharmaceuticals by 30.3% during the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 2,465 shares during the period. Legal & General Group Plc boosted its position in shares of Dicerna Pharmaceuticals by 38.7% during the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 2,561 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dicerna Pharmaceuticals by 512.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 2,894 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Dicerna Pharmaceuticals by 19.9% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 3,024 shares during the period. Finally, American International Group Inc. boosted its position in shares of Dicerna Pharmaceuticals by 17.6% during the fourth quarter. American International Group Inc. now owns 35,409 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 5,291 shares during the period. Institutional investors own 92.81% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Story: Balanced Fund

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.